Importance Imaging biomarkers in Parkinson disease (PD) are increasingly important for
monitoring progression in clinical trials and also have the potential to improve clinical care …

Iron has been increasingly implicated in the pathology of neurodegenerative diseases. In
the past decade, development of the new magnetic resonance imaging technique …

Parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the
midbrain. There are various imaging markers for Parkinson disease. Recent advances in …

A major challenge in Parkinson's disease is the variability in symptoms and rates of
progression, underpinned by heterogeneity of pathological processes. Biomarkers are …

Background The objective of this study was to determine whether neurotoxic kynurenine
metabolites, induced by inflammation, in plasma and cerebrospinal fluid (CSF) are …

A key aim in epidemiological neuroscience is identification of markers to assess brain health
and monitor therapeutic interventions. Quantitative susceptibility mapping (QSM) is an …

Background Higher nigral iron has been reported in Parkinson's disease (PD). Objective
The aim is to understand the dynamics of nigral iron accumulation in PD and its association …

Diagnosing early stage Parkinson's disease (PD) is still a clinical challenge. Previous
studies using iron, neuromelanin (NM) or the Nigrosome-1 (N1) sign in the substantia nigra …

The recent validation of the α-synuclein seed amplification assay as a biomarker with high
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …

Background: Parkinson's disease (PD) is a progressive neurodegenerative disease whose
main neuropathological feature is the loss of dopaminergic neurons of the substantia nigra …